Cambridge, Mass.-based biotechnology firm expects to become Aone of the top 10 pharmaceutical companies,@ CEO Mark Levin declared at the Chase H&Q Healthcare Conference Jan. 10-13 in San Francisco. The firm anticipates gaining approval for at least two products in 2000 and plans to get Aat least 10 important molecules in the clinic@ this year, Levin said. Millennium=s nearest term project is the oncology agent Campath for the treatment of fludarabine-refractory chronic lymphocytic leukemia, which will be copromoted by Schering AG. Millennium acquired Campath with its acquisition of LeukoSite in the fall of 1999. FDA has designated Campath for a fast track review; it could be approved by mid-2000 (AThe Pink Sheet@ Aug. 30, 1999, p. 21)
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth